J 2021

The Role of Circulating MicroRNAs in Patients with Early-Stage Pancreatic Adenocarcinoma

EID, Michal, Paraskevi KAROUSI, Lumír KUNOVSKÝ, Štěpán TUČEK, Dagmar BRANČÍKOVÁ et. al.

Basic information

Original name

The Role of Circulating MicroRNAs in Patients with Early-Stage Pancreatic Adenocarcinoma

Authors

EID, Michal (203 Czech Republic, belonging to the institution), Paraskevi KAROUSI, Lumír KUNOVSKÝ (203 Czech Republic, belonging to the institution), Štěpán TUČEK (203 Czech Republic, belonging to the institution), Dagmar BRANČÍKOVÁ (203 Czech Republic, belonging to the institution), Zdeněk KALA (203 Czech Republic, belonging to the institution), Ondřej SLABÝ (203 Czech Republic, belonging to the institution), Jiří MAYER (203 Czech Republic, belonging to the institution), Christos K. KONTOS (guarantor) and Jan TRNA (203 Czech Republic, belonging to the institution)

Edition

Biomedicines, Basel, MDPI, 2021, 2227-9059

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

10608 Biochemistry and molecular biology

Country of publisher

Switzerland

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

Impact factor

Impact factor: 4.757

RIV identification code

RIV/00216224:14110/21:00122646

Organization unit

Faculty of Medicine

UT WoS

000716958200001

Keywords in English

pancreatic cancer; early stage; microRNA; diagnosis; prognosis; chemoresistance

Tags

International impact, Reviewed
Změněno: 7/12/2021 13:36, Mgr. Tereza Miškechová

Abstract

V originále

Pancreatic ductal adenocarcinoma (PDAC) is increasing in incidence and is still associated with a high rate of mortality. Only a minority of patients are diagnosed in the early stage. Radical surgery is the only potential curative procedure. However, radicality is reached in 20% of patients operated on. Despite the multidisciplinary approach in resectable tumors, early tumor recurrences are common. Options on how to select optimal candidates for resection remain limited. Nevertheless, accumulating evidence shows an important role of circulating non-coding plasma and serum microRNAs (miRNAs), which physiologically regulate the function of a target protein. miRNAs also play a crucial role in carcinogenesis. In PDAC patients, the expression levels of certain miRNAs vary and may modulate the function of oncogenes or tumor suppressor genes. As they can be detected in a patient’s blood, they have the potential to become promising non-invasive diagnostic and prognostic biomarkers. Moreover, they may also serve as markers of chemoresistance. Thus, miRNAs could be useful for early and accurate diagnosis, prognostic stratification, and individual treatment planning. In this review, we summarize the latest findings on miRNAs in PDAC patients, focusing on their potential use in the early stage of the disease.

Links

MUNI/A/1595/2020, interní kód MU
Name: Nové přístupy ve výzkumu, diagnostice a terapii hematologických malignit VIII (Acronym: VýDiTeHeMa VIII)
Investor: Masaryk University